Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

REPL Stock Plunge: What’s Next?

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 7/30/2025, 9:19 am ET | 5 min
REPL Stock Plunge: What’s Next? Thumbnail

In this article

  • REPL+100.27%
    REPL - NYSEReplimune Group Inc.
    $7.51+3.76 (+100.27%)
    Volume:  114.40M
    Float:  52.19M
    $4.15Day Low/High$7.75

Replimune Group Inc. stocks have been trading up by 74.93% following FDA designations and promising clinical results.

  • 16 new non-executive staff were brought onto Replimune’s team with inducement equity awards, including stock options, under their Inducement Plan to attract new talent.

  • Following a significant drop in Replimune’s stock price, a class-action lawsuit has been launched. The lawsuit arose from the FDA’s rejection of RP1 for advanced melanoma, which had previously been expected to gain approval based on earlier studies.

Candlestick Chart

Live Update At 09:19:15 EST: On Wednesday, July 30, 2025 Replimune Group Inc. stock [NASDAQ: REPL] is trending up by 74.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview

In the world of trading, staying calm and waiting for the right moment is crucial. As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.” By adhering to this principle, traders can avoid impulsive decisions that often lead to significant losses. Understanding market dynamics and exercising patience can significantly enhance a trader’s success rate, allowing them to capitalize on opportunities when they align perfectly with their strategies.

Replimune Group Inc. reflects a story characterized by recent turbulence. A shift in valuation has been marked by a dramatic depreciation. This may initially stem from the FDA’s decision regarding their innovative drug. Let’s dissect the numbers to better understand Replimune’s current standing.

Recent Price Movements

Over a brief period, REPL’s daily price showed fascinating movement. Prices varied from a high of around $13.24 to lows plummeting to below $3. The drastic fluctuation primarily emanated from news regarding the official response to the RP1 treatment. Up until the day before, the price loosely lingered between ranges, showing the volatile nature influenced by both insider and broader market sentiments.

Key Ratios and Financial Metrics

Examining the financial metrics, Replimune reveals a challenging position. Though their current ratio indicates they can readily cover short-term liabilities with existing assets, significant losses and negative returns paint a broader picture of issues that question its long-term sustainability. Their leverage ratio implies they’re relying on debt, a situation worsened by lowered revenues and growing expenditures, which can deter long-term investors.

More Breaking News

Cash Flow and Financial Reports

Replimune’s cash flow displays hefty dimensions to consider. A considerable cash decrease worth $61.4M spells liquidity updates, impacted by considerable investments which may need close examination for their return potential. While revenue streams can’t currently sustain expenditures, market participants hope for upcoming revisions in approach and focus to shore up confidence.

Market Sentiments and Impact

Navigating the complexity and fervor of Replimune’s current standing is a task of balancing emotive industry events and realistic hopes. Recent setbacks may discourage newcomers. Among existing stakeholders, loyalty could be tested as outcomes of court disputes brew further uncertainty. However, optimism might linger with enhanced executive strategies, possibly inviting excitement should future developments align with decisive improvements in drug approval workflows and market participation.

Assumptions and Conclusions

In conclusion, Replimune appears at a critical juncture. The excitement around medical innovation faces headwinds with official challenges. But with balanced fiscal steps and management choices, it could navigate through present intricacies to realign towards sustainable objectives. For those in the trading realm, this period reflects a vivid illustration of the interplay between medical advancements, regulatory determinations, and the market’s pulse of anticipation. As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.” As the dust settles, observers may anticipate cautious recalibrations from stakeholders eying the horizon for any silver linings ahead.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

In this article (YTD Performance)

  • REPL-73.82%
    REPL - NYSEReplimune Group Inc.
    $7.51+3.76 (+100.27%)
    Volume:  114.40M
    Float:  52.19M
    $4.15Day Low/High$7.75

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications